While PAR2 antagonists such as PZ-235 have demonstrated in vivo efficacy in mouse models of atopic dermatitis [31], their clinical translation has been limited by poor stability, suboptimal oral bioavailability, and formulation hurdles. The gene discussed is F2RL1; the disease is atopic eczema.